ArticleACS medicinal chemistry letters2019
Novel Phenyldiazenyl Fibrate Analogues as PPAR α/γ/δ Pan-Agonists for the Amelioration of Metabolic Syndrome.
Article in ACS medicinal chemistry letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Design, synthesis and biological evaluation of novel dualaction statin conjugates with triglyceride and cholesterol lowering activities.Molecular diversity · 2025Article
- Azobenzene as Multi-Targeted Scaffold in Medicinal Chemistry.Molecules (Basel, Switzerland) · 2024Review
- Radiolabeled Probes from Derivatives of Natural Compounds Used in Nuclear Medicine.Molecules (Basel, Switzerland) · 2024Review
- Azobenzenesulfonamide Carbonic Anhydrase Inhibitors as New Weapons to FightPharmaceuticals (Basel, Switzerland) · 2024Article
- The Small Molecule PPARγ Agonist GL516 Induces Feeding-Stimulatory Effects in Hypothalamus Cells Hypo-E22 and Isolated Hypothalami.Molecules (Basel, Switzerland) · 2022Article
- Synthesis, In Vitro, In Vivo and In Silico Antidiabetic Bioassays of 4-Nitro(thio)phenoxyisobutyric Acids Acting as Unexpected PPARγ Modulators: An In Combo Study.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Structural Basis for PPARs Activation by The Dual PPARα/γ Agonist Sanguinarine: A Unique Mode of Ligand Recognition.Molecules (Basel, Switzerland) · 2021Article
- Design, Synthesis and Biological Evaluation of Aromatase Inhibitors Based on Sulfonates and Sulfonamides of Resveratrol.Pharmaceuticals (Basel, Switzerland) · 2021Article
- A Novel N-Substituted Valine Derivative with Unique Peroxisome Proliferator-Activated Receptor γ Binding Properties and Biological Activities.Journal of medicinal chemistry · 2020Article
- Sulfonimide and Amide Derivatives as Novel PPARα Antagonists: Synthesis, Antiproliferative Activity, and Docking Studies.ACS medicinal chemistry letters · 2020Article
- Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.MedChemComm · 2019Article
- Lifestyle and Food Habits Impact on Chronic Diseases: Roles of PPARs.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of PPARα/γ dual or PPARα/γ/δ pan-agonists could represent an efficacious approach for a simultaneous pharmacological intervention on carbohydrate and lipid metabolism. Two series of new phenyldiazenyl fibrate derivatives of GL479, a previously reported PPARα/γ dual agonist, were synthesized and tested. Compound
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.